CAMBRIDGE, Mass. and INDIANAPOLIS, Sept. 27, 2017 (GLOBE NEWSWIRE)-Novaseek Research, Inc., a health IT for life sciences company, and hc1.com, inventor of the healthcare relationship management (HRM) platform, announced a partnership to help hospitals and clinical labs enhance their operations through improved performance and additional revenue streams. The collaboration enables hospitals and clinical labs to contribute to research by maximizing use of clinical information and lab specimens while reducing costs and growing lab revenue.
“Together Novaseek Research and hc1.com offer unprecedented value to hospitals and clinical labs that are under increased pressure to meet greater demands while facing reduced reimbursements,” said Andrei Soran, Chief Executive Officer, Novaseek Research. “The technology solutions provided via this partnership offer labs a full range of options for improving financial and operational efficiencies while empowering them to take a bigger role in advancing precision medicine using real world data.”
“The hc1.com platform enables labs to improve performance while identifying opportunities to increase profitable growth,” said Brad Bostic, founder and CEO of hc1.com. “Through our alliance with Novaseek, labs can now generate revenue by repurposing remnant clinical specimens, increasing the value of their work to the healthcare community while increasing revenue.”
Novaseek’s Clinical Data Network for Research (CDNR) platform is a cloud-based platform that transforms the way healthcare organizations and consented patients share biospecimens and clinical data with the research community. The platform constantly scans for laboratory biospecimens that match researchers’ detailed clinical criteria, automating what was once a manual process of biospecimen selection and chart reviews. The CDNR makes it possible to fulfill complex requests, accelerating research and driving additional revenue for clinical labs as they assume a greater role supporting biomedical research.
About hc1.com
The hc1® Healthcare Relationship Cloud® enables health systems, diagnostic labs, and post acute care organizations to grow profitably and deliver amazing service. hc1 has been adopted across more than 1,000 locations across the globe, including Cleveland Clinic, Alere, Nationwide Children’s Hospital, and Sonic Healthcare. The company has received accolades from Gartner Research, was named “Best Healthcare CRM for Diagnostic Laboratories” by Frost & Sullivan, and is the current KLAS Healthcare CRM category leader. To learn more, visit www.hc1.com and follow us on Twitter @hc1_HRM, LinkedIn, and Facebook.
About CDNR
Novaseek’s award-winning novel cloud platform, the Clinical Data Network for Research (CDNR), easily interfaces with hospital data sources in real time to support research and biobanking workflows before, during, and after a study. CDNR enables researchers to define patient cohorts through population analytics, access consented biospecimens and data, and advance translational medicine, clinical development, and observational studies. CDNR’s new and improved solution uses historical data and interactive analytics to meet the overlapping needs of organizations involved in clinical data.
About Novaseek
Novaseek Research, Inc. is a game-changing health IT for life sciences company that provides turn-key, dynamic access to real world clinical data and biospecimens from a network of healthcare organizations. We envision a world where a clear understanding of real-world patients is central to every stage of life sciences research and drug development. For more information, please visit www.novaseekresearch.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.